Eprosartan
Angiotensin II receptor antagonist
- US DailyMed: Eprosartan
category
- AU: D
administration
- C09CA02 (WHO)
- AU: S4 (Prescription only)
- US: ℞-only
- 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
- 133040-01-4
Y
- 5281037
- 588
- DB00876 Y
- 4444504 Y
- 2KH13Z0S0Y
- D04040 Y
- as mesylate: D02082 Y
- CHEBI:4814 Y
- ChEMBL813 Y
- DTXSID0022989
- Interactive image
- O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
- InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+Y
- Key:OROAFUQRIXKEMV-LDADJPATSA-NY
Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.[1]
Eprosartan is sometimes paired with hydrochlorothiazide.[2]
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[3]
History
The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[4]
References
- ^ "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.
- ^ "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.
- ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.
- ^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [1], accessed 29 January 2015.
- v
- t
- e
("-pril")
- Sulfhydryl-containing: Captopril
- Rentiapril
- Zofenopril
- Dicarboxylate-containing: Enalapril#
- Benazepril
- Cilazapril
- Delapril
- Imidapril
- Lisinopril (+amlodipine, +HCT)
- Moexipril
- Perindopril (+indapamide)
- Quinapril (+HCT)
- Ramipril
- Spirapril
- Temocapril
- Trandolapril
- Phosphonate-containing: Ceronapril
- Fosinopril (+HCT)
- Other/ungrouped: Alacepril
("-sartan")
("-kiren")
- Gemopatrilat
- Ilepatril
- Omapatrilat
- Sampatrilat
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Portal:
Medicine
